Last reviewed · How we verify
NCT06957145
Vista Protein Expression of Monocyte and T Cell Subsets in Multiple Sclerosis and Its Clinical Correlation
trial in Multiple Sclerosis, MS in 60 participants. Currently enrolling.
30 January 2026
Quick facts
| Lead sponsor | Koç University |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 60 |
| Start date | 30 June 2025 |
| Primary completion | 30 January 2026 |
| Estimated completion | 30 December 2026 |
| Sites | 2 locations across Turkey (Türkiye) |
Conditions studied
- Multiple Sclerosis, MS — all drugs for Multiple Sclerosis, MS →
Sponsor
Koç University
Who can join
18 and older, any sex, with Multiple Sclerosis, MS. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The aim of this study is to investigate whether VISTA, a newly identified negative immune regulatory protein, differs in monocytes and T cells of patients diagnosed with Multiple Sclerosis (MS) and Clinically Isolated Syndrome (CIS) compared to the same cell types in healthy controls. Additionally, the potential clinical correlation of VISTA expression in the follow-up of MS and CIS patients will be examined. By elucidating the role of VISTA in the pathophysiology of MS, this study will contribute to the literature by exploring its potential as a biomarker and its relevance in the development of novel therapeutic strategies. Specifically, this study will compare VISTA protein secretion in MS patients at the time of their first attack with that of healthy controls. Furthermore, changes in VISTA protein secretion will be assessed in blood samples collected at 6- and 12-month follow-ups, and the correlations of these changes with clinical and laboratory findings will be investigated. Finally, this study aims to determine whether CD4+ and CD8+ T cells, monocytes, and T regulatory (Treg) subgroups in the first attack blood samples of MS patients exhibit similar functional properties in terms of VISTA protein secretion as their counterparts in healthy controls. To achieve this, monocytes and T cell subtypes will be stimulated, and their pro- and anti-inflammatory cytokine responses will be analyzed.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06957145
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Multiple Sclerosis, MS
Currently open trials in the same condition.
- NCT06800144 — Effect of Music Therapy on Pain in People With Multiple Sclerosis · NA · recruiting
- NCT06860932 — A Palliative Care Model Impact on Knowledge and Attitudes · NA · recruiting
- NCT06839924 — Effect of Motor Cognitive Interference on Cognition and Quality of Life on Patients with Multiple Sclerosis · NA · active not recruiting
- NCT06541626 — Sun Yat-Sen Cohort of CNS Idiopathic Inflammatory Demyelinating Diseases · recruiting
Other Koç University trials
Trials by the same sponsor.
- NCT07528976 — Effect of Peer Education on Climate Change Awareness and Anxiety in Nursing Students · NA · recruiting
- NCT07445711 — Effect of Guided Imagery and AI-Assisted Video on Pain During Uterine Involution Assessment in Postpartum Women: A Rando · NA · not yet recruiting
- NCT07341113 — Positional Effects on Lung Ventilation and Perfusion in Obesity · completed
- NCT07171944 — Effects of Artificial Intelligence Nurse Orientation Program on Psychological Outcomes and Length of Hospital Stay in In · NA · not yet recruiting
- NCT07409818 — A Novel Classification in Calcific Tendinitis of the Shoulder: Evaluating MRI Localization and Related Treatment Strateg · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06957145 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Koç University
- Last refreshed: 3 September 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06957145.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing